These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18383843)

  • 1. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
    Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
    Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
    Nakata B; Amano R; Nakao S; Tamura T; Shinto O; Hirakawa T; Okita Y; Yamada N; Hirakawa K
    J Exp Clin Cancer Res; 2010 Feb; 29(1):15. PubMed ID: 20181235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
    Okamura Y; Yasukawa S; Narimatsu H; Boku N; Fukutomi A; Konishi M; Morinaga S; Toyama H; Kaneoka Y; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Kainuma O; Hishinuma S; Yamaguchi R; Nagino M; Hirano S; Yanagisawa A; Mori K; Uesaka K
    Cancer Sci; 2020 Feb; 111(2):548-560. PubMed ID: 31778273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental study of combination therapy with S-1 against pancreatic cancer.
    Yoshizawa J; Takizawa A; Takeuchi O; Hiraku O; Sasaki K; Morimoto Y; Atsuda K; Inoue G; Suzuki Y; Asanuma F; Yamada Y
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1211-9. PubMed ID: 19337733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
    Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
    Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatments of pancreatic cancer from the standpoint of medical oncology].
    Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):997-1001. PubMed ID: 17637534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
    Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
    Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
    Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
    Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
    Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
    Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
    Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
    Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
    Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
    Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells.
    Hioki M; Shimada T; Yuan T; Nakanishi T; Tajima H; Yamazaki M; Yokono R; Takabayashi M; Sawamoto K; Akashita G; Miyamoto KI; Ohta T; Tamai I; Shimada T; Sai Y
    Biopharm Drug Dispos; 2018 May; 39(5):256-264. PubMed ID: 29682747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
    Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
    Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.
    Yang Y; Tian W; Yang L; Zhang Q; Zhu M; Liu Y; Li J; Yang L; Liu J; Shen Y; Qi Z
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):93-103. PubMed ID: 32897433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
    Kuji M; Yamamoto Y; Tani C; Kenno S; Kobayashi T
    Gan To Kagaku Ryoho; 2011 May; 38(5):853-5. PubMed ID: 21566453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
    Eto K; Kawakami H; Kuwatani M; Kudo T; Abe Y; Kawahata S; Takasawa A; Fukuoka M; Matsuno Y; Asaka M; Sakamoto N
    Br J Cancer; 2013 Apr; 108(7):1488-94. PubMed ID: 23492684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.